Publication details

CTRP1: A Molecular Link between Obesity and Hypertension

Title in English CTRP1: A Molecular Link between Obesity and HypertensionCha
Authors

CHALUPOVÁ Lenka HALUPOVÁ H. ŽÁKOVSKÁ Alena KREJČÍ G. ŠVESTÁK M. STEJSKAL D.

Year of publication 2016
Type Article in Periodical
Magazine / Source J Mol Biomark Diagn
MU Faculty or unit

Faculty of Science

Citation
Field Immunology
Keywords CTRP1; Aldosterone; ELISA; Obesity; Hypertension; Metabolic syndrome; Diabetic nephropathy
Description Abstract Background: CTRP1, a recently identified adipokine, was found to stimulate aldosterone production. Serum CTRP1 and plasma Aldosterone levels were significantly increased in patients with diabetes mellitus and metabolic syndrome. Therefore, it would be interesting to investigate whether the secretion of CTRP1 in human serum is associated with hypertension as well as with diabetes mellitus. Aim: This study evaluated serum CTRP1 and aldosterone concentrations in healthy individuals and in patients with diabetic nephropathy. Methods: Serum samples from 32 healthy individuals and 44 patients with diabetic nephropathy were measured for CTRP1, Aldosterone, diabetes-related biomarkers and renal disease-related biomarkers by enzyme-linked immunosorbent assay (ELISA). Results: Correlation analyses showed that serum CTRP1 in healthy individuals was not correlated with any other biochemical parameters or laboratory characteristic; however, in patients with diabetic nephropathy, a significant correlation was found between serum CTRP1 and Aldosterone (P=0.003), Urea, Cystatin C and ANGPTL4. Aldosterone level was significantly higher in subjects with diabetic nephropathy compared to healthy subjects (P=0.01). Discussion: Our results demonstrated that the adipokine CTRP1 is significantly associated with Aldosterone and support the hypothesis that CTRP1 may be a newly identified molecular link between obesity and hypertension.

You are running an old browser version. We recommend updating your browser to its latest version.

More info